NASDAQ:TPST Tempest Therapeutics Q4 2024 Earnings Results & Report $0.64 0.00 (-0.03%) Closing price 04:00 PM EasternExtended Trading$0.64 +0.01 (+0.94%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tempest Therapeutics missed analyst earnings expectations in its Q4 2024 results, released March 27, 2025. The company reported EPS of -$4.03 versus the -$3.12 consensus estimate, while revenue was $0.49 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 27, 2025TimeBefore Market OpensConference Call4:00 PM ET Tempest Therapeutics EPS ResultsActual EPS-$4.03Consensus EPS -$3.12Beat/MissMissed by -$0.91One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersTempest Therapeutics Revenue ResultsActual Revenue$0.49 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTempest Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tempest Therapeutics Q4 2024 Earnings FAQ Did Tempest Therapeutics beat earnings estimates for Q4 2024? Tempest Therapeutics (NASDAQ:TPST) reported earnings of -$4.03 per share for Q4 2024, missing the consensus estimate of -$3.12. The report was announced on Thursday, March 27, 2025. What was Tempest Therapeutics' revenue for Q4 2024? Tempest Therapeutics reported revenue of $0.49 million for Q4 2024. When is Tempest Therapeutics' next earnings date? Tempest Therapeutics' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Tempest Therapeutics on the company's earnings history page. Tempest Therapeutics Earnings HeadlinesTempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets ExpertiseOctober 14 at 8:00 AM | globenewswire.comTempest Therapeutics (NASDAQ:TPST) Upgraded to Sell at Wall Street ZenOctober 10, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 15 at 1:00 AM | Stansberry Research (Ad)Tempest Therapeutics consensus price target decreased by 36.36% to $7.14October 2, 2026 | msn.comTempest Appoints Global Finance Leader Nancy Freda-Smith to Board of DirectorsSeptember 23, 2026 | globenewswire.comTempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T PlatformSeptember 16, 2026 | finanznachrichten.deSee More Tempest Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tempest Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tempest Therapeutics and other key companies, straight to your email. Email Address About Tempest TherapeuticsTempest Therapeutics (NASDAQ:TPST) is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue. Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). The company has evaluated TPST-1120 as a monotherapy and in combination with immune checkpoint inhibitors for advanced solid tumors, including hepatocellular carcinoma. Tempest has also developed additional early-stage oncology programs, including TPST-1495, an investigational small-molecule inhibitor of cyclooxygenase enzymes. Founded in 2018 and headquartered in the United States, Tempest advances its programs through clinical studies conducted in collaboration with medical centers and research partners. Its activities are primarily focused on the development of therapies for patients with advanced cancers rather than on commercialized products. Stephen Brady has served as the company’s president and chief executive officer.View Tempest Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
